• Hanmi Pharmaceutical’s board approved cancellation of 85,316 common shares on Oct. 27, 2026.
• The cancellation covers previously acquired treasury shares with a book value of KRW 28.27 billion.
• Total issued common shares stand at 12,810,991, with a par value of KRW 2,500 per share.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Hanmi Pharmaceutical Co. Ltd. published the original content used to generate this news brief via DART, the regulatory disclosure system operated by the South Korea Financial Supervisory Service (FSS) (Ref. ID: 20261027800662), on October 27, 2026, and is solely responsible for the information contained therein.